


TABLE OF CONTENTS

1. CLINICAL INDIVIDUAL HEALTH4



2. REFERENCES56

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 2 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

LIST OF FIGURES

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Figure 15


Figure 16

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 3 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0



LIST OF TABLES

Table 1

Table 2

Table 3

Table 4


Table 5

Table 6

Table 7

Table 8

Table 9



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 4 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

1. CLINICAL INDIVIDUAL HEALTH

1.1. Additional Studies Completed after Issuance of the MRGO

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 5 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 6 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 7 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 8 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 9 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 10 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 11 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 12 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 13 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 14 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 15 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 16 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 17 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 18 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 19 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 20 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 21 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 22 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 23 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 24 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 25 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 26 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 27 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 28 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 29 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 30 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 31 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 32 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 33 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 34 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 35 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 36 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 37 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 38 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 39 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 40 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 41 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 42 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 43 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 44 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 45 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 46 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 47 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 48 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 49 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 50 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 51 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 52 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 53 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 54 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)



Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 55 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

(b) (4)




Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 56 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

1.1.7. Overall Conclusions of the New Studies



2. REFERENCES

1. Global initiative for Chronic Obstructive Lung Disease: GOLD, *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. Updated 2013*. 2013.
2. Society for Research on Nicotine and Tobacco Subcommittee on Biochemical Verification, et al., *Biochemical verification of tobacco use and cessation*. Nicotine and Tobacco Research, 2002. 4(2): p. 149-159.
3. Berg, C., et al., *Correlates of NNAL levels among nondaily and daily smokers in the college student population*. Current Biomarker Findings, 2012. 2: p. 87-94.
4. Roemer, E., et al., *Scientific assessment of the use of sugars as cigarette tobacco ingredients: a review of published and other publicly available studies*. Crit Rev Toxicol, 2012. 42(3): p. 244-78.
5. U.S. Department of Health and Human Services, *Smoking cessation: a report of the Surgeon General*, in *Smoking cessation: a report of the Surgeon General*. 2020, US Department of Health and Human Services: Washington (DC).
6. Thomas, E.T., et al., *Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies*. BMJ Open, 2019. 9(6): p. e028150.
7. Theophilus, E.H., et al., *Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: a one-week clinical confinement study*. Regulatory Toxicology and Pharmacology, 2015. 71(2): p. 225-34.
8. Rostron, B.L., et al., *Associations of cigarettes smoked per day with biomarkers of exposure among US adult cigarette smokers in the population assessment of tobacco and health (PATH) study wave 1 (2013-2014)*. Cancer Epidemiol Biomarkers Prev, 2019.
9. Johannsen, A., C. Susin, and A. Gustafsson, *Smoking and inflammation: evidence for a synergistic role in chronic disease*. Periodontol 2000, 2014. 64(1): p. 111-26.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 57 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

10. Ojima, M., et al., *Relationship between smoking status and periodontal conditions: findings from national databases in Japan*. J Periodontol Res, 2006. **41**(6): p. 573-9.
11. Torrungruang, K., et al., *The effect of cigarette smoking on the severity of periodontal disease among older Thai adults*. J Periodontol, 2005. **76**(4): p. 566-72.
12. Warnakulasuriya, S., et al., *Oral health risks of tobacco use and effects of cessation*. Int Dent J, 2010. **60**(1): p. 7-30.
13. Preshaw, P.M., et al., *Progression and treatment of chronic adult periodontitis*. J Periodontol, 1999. **70**(10): p. 1209-20.
14. Nair, P., et al., *Gingival bleeding on probing increases after quitting smoking*. J Clin Periodontol, 2003. **30**(5): p. 435-7.
15. Fiorini, T., *Smoking cessation may promote additional benefits to non-surgical periodontal therapy in adults with chronic periodontitis*. J Evid Based Dent Pract, 2015. **15**(2): p. 83-4.
16. Fiorini, T., et al., *Is there a positive effect of smoking cessation on periodontal health? A systematic review*. J Periodontol, 2014. **85**(1): p. 83-91.
17. Grossi, S.G., et al., *Effects of smoking and smoking cessation on healing after mechanical periodontal therapy*. J Am Dent Assoc, 1997. **128**(5): p. 599-607.
18. Hughes, F.J., et al., *Prognostic factors in the treatment of generalized aggressive periodontitis: II. Effects of smoking on initial outcome*. J Clin Periodontol, 2006. **33**(9): p. 671-6.
19. Labriola, A., I. Needleman, and D.R. Moles, *Systematic review of the effect of smoking on nonsurgical periodontal therapy*. Periodontol 2000, 2005. **37**: p. 124-37.
20. Lüdicke, F., et al., *Effects of Switching to the Tobacco Heating System 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1)*. Nicotine Tob Res, 2018. **20**(2): p. 161-172.
21. Haziza, C., et al., *Reduction in exposure to selected Harmful and Potentially Harmful Constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (part 1)*. Nicotine Tob Res, 2019. **22**(4): p. 539-548.
22. Lüdicke, F., et al., *Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate modified risk tobacco product: a randomized trial*. Cancer Epidemiology, Biomarkers & Prevention, 2019. **28**(11): p. 1934-43.
23. Preus, H.R., et al., *Baseline adjustment and change revisited: effect of smoking on change in periodontal status following periodontal therapy*. Eur J Oral Sci, 2014. **122**(2): p. 89-99.
24. Philip Morris Products S.A., *Effect of switching from cigarette smoking to the use of IQOS on periodontitis treatment outcome (P1-OHS-01-JP)*. 2022. In: **ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2023 Jan 24]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03364751> Identifier: NCT0336471.**

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 58 of 58
7-a07-clin-ind-health-additional-studies	Version 1.0

25. Pouly, S., et al., *Effect of switching from cigarette smoking to the use of the Tobacco Heating System on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study*. Frontiers in Dental Medicine, 2022: p. 51.
26. Hoyt, G.L., *Cigarette smoking: nicotine, carbon monoxide, and the physiological effects on exercise responses*. Vol. XXII. 2013.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.
